SARS-CoV-2 & Influenza A/B Antigen Rapid Test – 3 results from 1 sample (15 pieces)

 90,75  75,00 ex. VAT

The OnSite COVID-19 + Influenza A/B Antigen Rapid Test is a lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens and the qualitative detection and differentiation of Influenza A (including H5N1 and H1N1) and Influenza B viral antigens in nasopharyngeal (NP) or nasal swab specimens.

In stock (can be backordered)

For health care professionals and trained personnel only. First shipment out: November 7th 2021. 

The OnSite COVID-19 + Influenza A/B Antigen Rapid Test is a lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid antigens and the qualitative detection and differentiation of Influenza A (including H5N1 and H1N1) and Influenza B viral antigens in nasopharyngeal (NP) or nasal swab specimens. 

The OnSite COVID-19 + Influenza Test:

  • Uses one sample for the diagnostics of 2 common diseases: COVID-19 and Influenza
  • Requires less invasive sampling (nasal swabs possible)
  • Is very easy to use
  • Is fast: results within 15-20 minutes

The immunoassay consists of 2 cassettes assembled into one panel (left side: Influenza A/B Rapid Test; right side: COVID-19 Ag Rapid Test). The specimen is collected with a nasopharyngeal or nasal swab and the SARS-CoV-2 nucleocapsid antigen and Influenza A and B antigens are extracted from the swab with extraction buffer. The test procedure is a very simple 9-step procedure, a simplified version of the preparation procedure can be found below:

Results are visible after only 15 minutes and result interpretation is very easy.

  • Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial or viral infections.
  • Negative results from patients with symptom onset beyond seven days should be confirmed with a molecular assay. Negative results do not rule out infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19 and/or Influenza A/B.

The product is intended to be used in any laboratory and non-laboratory environment that meets the requirements specified in the Instructions for Use and local regulations. For in vitro diagnostic use only.